Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: An immunohistochemical and RT-PCR study

American Journal of Surgical Pathology

Volumn 32, Issue 9, 2008, Pages 1344-1352

  Rodriguez, Fausto J ^a   Scheithauer, Bernd W ^a   Roncaroli, Federico ^b   Silva, Ana I ^c   Kovacs, Kalman ^d   Brat, Daniel J ^e   Jin, Long ^a  

^a MAYO CLINIC   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c HOSPITAL DE BRAGA   (Portugal)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Differential diagnosis; Galectin 3; Immunohistochemistry; Nervous system; RT PCR; Sella; Tumor

Indexed keywords

GALECTIN 3; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; GRANULAR CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MENINGIOMA; METASTASIS; NERVE SHEATH TUMOR; NERVOUS SYSTEM; ONCOCYTOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELLA TURCICA TUMOR; SPINDLE CELL; BIOSYNTHESIS; BRAIN TUMOR; METABOLISM; PATHOLOGY; SELLA TURCICA;

BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; NERVE SHEATH NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SELLA TURCICA; TUMOR MARKERS, BIOLOGICAL;

EID: 52149115131     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181694f41     Document Type: Article

References (35)

1. Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994;269: 20807-20810.
2. Bigotti G, Coli A, Del Vecchio M, et al. Evaluation of galectin-3 expression by sarcomas, pseudosarcomatous and benign lesions of the soft tissues. Preliminary results of an immunohistochemical study. J Exp Clin Cancer Res. 2003;22:255-264.
3. Brat DJ, Scheithauer BW, Staugaitis SM, et al. Pituicytoma: a distinctive low-grade glioma of the neurohypophysis. Am J Surg Pathol. 2000;24:362-368.
4. Bresalier RS, Yan PS, Byrd JC, et al. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer. 1997;80: 776-787.
5. Bresalier RS, Mazurek N, Sternberg LR, et al. Metastasis of human colon cancer is altered by modifying expression of the betagalactoside-binding protein galectin 3. Gastroenterology. 1998;115: 287-296.
6. Camby I, Belot N, Rorive S, et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol. 2001;11:12-26.
7. Das A, Tan WL, Smith DR. Expression of extracellular matrix markers in benign meningiomas. Neuropathology. 2003;23:275-281.
8. Deininger MH, Trautmann K, Meyermann R, et al. Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. Anticancer Res. 2002;22:1585-1592.
9. Feilchenfeldt J, Tötsch M, Sheu SY, et al. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod Pathol. 2003;16:1117-1123.
10. Gordower L, Decaestecker C, Kacem Y, et al. Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol. 1999;25: 319-330.
11. Gotz W, Kasper M, Miosge N, et al. Detection and distribution of the carbohydrate binding protein galectin-3 in human notochord, intervertebral disc and chordoma. Differentiation. 1997;62:149-157.
12. Hancq S, Salmon I, Brotchi J, et al. S100A5: a marker of recurrence in WHO grade I meningiomas. Neuropathol Appl Neurobiol. 2004; 30:178-187.
13. Hancq S, Salmon I, Brotchi J, et al. Detection of S100B, S100A6 and galectin-3 ligands in meningiomas as markers of aggressiveness. Int J Oncol. 2004;25:1233-1240.
14. Jin L, Riss D, Ruebel K, et al. Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas. Endocr Pathol. 2005;16: 107-114.
15. Juliao SF, Rand N, Schwartz HS. Galectin-3: a biologic marker and diagnostic aid for chordoma. Clin Orthop Rel Res. 2002;397: 70-75.
16. Kloub O, Perry A, Tu PH, et al. Spindle cell oncocytoma of the adenohypophysis: report of two recurrent cases. Am J Surg Pathol. 2005;29:247-253.
17. Kuklinski S, Pesheva P, Heimann C, et al. Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res. 2000;60:45-57.
18. Mathieu A, Saal I, Vuckovic A, et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcino-ma and squamous cell carcinoma of the lung. Mod Pathol. 2005;18:1264-1271.
19. McClung HM, Thomas SL, Osenkowski P, et al. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett. 2007;419:172-177.
20. Neder L, Marie SK, Carlotti CG Jr, et al. Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol. 2004;14:399-405.
21. Ochieng J, Green B, Evans S, et al. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta. 1998;1379:97-106.
22. Probstmeier R, Montag D, Schachner M. Galectin-3, a betagalactoside- binding animal lectin, binds to neural recognition molecules. J Neurochem. 1995;64:2465-2472.
23. Reichert F, Saada A, Rotshenker S. Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose-specific lectin MAC-2. J Neurosci. 1994;14: 3231-3245.
24. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003;63:2251-2255.
25. Roncaroli F, Scheithauer BW, Cenacchi G, et al. 'Spindle cell oncocytoma' of the adenohypophysis: a tumor of folliculostellate cells? Am J Surg Pathol. 2002;26:1048-1055.
26. Ruebel KH, Jin L, Qian X, et al. Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res. 2005;65: 1136-1140.
27. Ruebel KH, Leontovich AA, Jin L, et al. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine. 2006;29:435-444.
28. Schwarz G Jr, Remmelink M, Decaestecker C, et al. Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign versus malignant uterine smooth muscle tumors. Am J Clin Pathol. 1999; 111:623-631.
29. Silva AI, Scheithauer BW, Lloyd RV, et al. Spindle cell oncocytoma of the sella with marked pleomorphism (abstract). Neuropathol Applied Neurobiol. 2006;32:232.
30. Strik HM, Deininger MH, Frank B, et al. Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol. 2001;53:13-20.
31. Teymoortash A, Pientka A, Schrader C, et al. Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol. 2006; 132:51-56.
32. Thodou E, Argyrakos T, Kontogeorgos G. Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens). 2007;6:227-232.
33. Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815-822.
34. Xu XC, Sola Gallego JJ, Lotan R, et al. Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms. Int J Oncol. 2000;17:271-276.
35. Yoshii T, Fukumori T, Honjo Y, et al. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2002;277:6852-6857.